The U.S. Preventive Services Task Force updated its breast cancer screening guidance, saying women should now be screened at age 40 instead of 50. The task force says the earlier screening could save up to 19% more lives. (CNBC)
Johnson & Johnson’s Tremfya succeeded in a late-stage trial for ulcerative colitis. Results from the Quasar induction study showed that 22.6% of those on Tremfya achieved clinical remission at week 12, the primary endpoint. (Seeking Alpha)
After Roe v. Wade was overturned, privacy advocates raised an alarm that data from smartphones could be used to help prosecute abortions. Google offered to proactively delete its trove of location data when people visited “particularly personal” places, including abortion clinics, hospitals and shelters. Nearly a year later, an investigation reveals Google isn’t doing that in any consistent way and its response shows it isn’t taking accountability. (The Washington Post)
Food and Drug Administration advisors will meet Friday to discuss Sarepta Therapeutics’ experimental gene therapy, SRP-9001, for Duchenne muscular dystrophy. SRP-9001 would be the first gene therapy to be given accelerated approval, if advisors decide the clinical evidence meets the bar. (STAT News)
A large trial added to evidence that many older men do not benefit from treatment for low-risk prostate cancer. Still, many of these men are still screened for the condition, and changing the practice has proven difficult. (The New York Times)
